SciSparc to Acquire Xylo’s MUSE Endoscopy IP Portfolio
Reuters
Nov 26
SciSparc to Acquire Xylo's MUSE Endoscopy IP Portfolio
SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. The MUSE™ system is a single-use, minimally invasive endoscopic device for treating gastroesophageal reflux disease (GERD) via transoral fundoplication. As consideration for the acquired assets, SciSparc will issue new ordinary shares representing 19.99% of its issued and outstanding share capital to Xylo, with the option to issue pre-funded warrants instead. Building on previous commercialization efforts in Greater China, SciSparc plans to expand the MUSE™ system's reach into additional global markets through exclusive regional partnerships.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592784-en) on November 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.